BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 18657086)

  • 1. Humoral and cellular immune monitoring might be useful to identify liver transplant recipients at risk for development of infection.
    Carbone J; Micheloud D; Salcedo M; Rincon D; Bañares R; Clemente G; Jensen J; Sarmiento E; Rodriguez-Molina J; Fernandez-Cruz E
    Transpl Infect Dis; 2008 Dec; 10(6):396-402. PubMed ID: 18657086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IgG monitoring to identify the risk for development of infection in heart transplant recipients.
    Sarmiento E; Rodriguez-Molina JJ; Fernandez-Yañez J; Palomo J; Urrea R; Muñoz P; Bouza E; Fernandez-Cruz E; Carbone J
    Transpl Infect Dis; 2006 Mar; 8(1):49-53. PubMed ID: 16623821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased levels of serum immunoglobulins as a risk factor for infection after heart transplantation.
    Sarmiento E; Rodríguez-Molina J; Muñoz P; Fernández-Yánez J; Palomo J; Fogueda M; Fernández-Cruz E; Bouza E; Carbone J
    Transplant Proc; 2005 Nov; 37(9):4046-9. PubMed ID: 16386623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternate-day prednisone in the maintenance immunosuppressive therapy after orthotopic liver transplantation.
    Pedrosa MC; Rohrer RM; Kaplan MM
    Clin Transplant; 1995 Aug; 9(4):322-5. PubMed ID: 7579741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation.
    Firpi RJ; Zhu H; Morelli G; Abdelmalek MF; Soldevila-Pico C; Machicao VI; Cabrera R; Reed AI; Liu C; Nelson DR
    Liver Transpl; 2006 Jan; 12(1):51-7. PubMed ID: 16382464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation.
    Sarmiento E; Lanio N; Gallego A; Rodriguez-Molina J; Navarro J; Fernandez-Yañez J; Palomo J; Rodríguez-Hernández C; Ruiz M; Alonso R; Fernandez-Cruz E; Carbone J
    Int Immunopharmacol; 2009 Jun; 9(6):649-52. PubMed ID: 18940269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma total homocysteine and cardiovascular risk in patients submitted to liver transplantation.
    Bianchi G; Nicolino F; Passerini G; Grazi GL; Zappoli P; Graziani R; Berzigotti A; Chianese R; Mantovani V; Pinna AD; Zoli M
    Liver Transpl; 2006 Jan; 12(1):105-11. PubMed ID: 16382457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained and focused hepatitis B virus nucleocapsid-specific T-cell immunity in liver transplant recipients compared to individuals with chronic and self-limited hepatitis B virus infection.
    Bihl F; Loggi E; Chisholm JV; Biselli M; Morelli MC; Cursaro C; Terrault NA; Bernardi M; Bertoletti A; Andreone P; Brander C
    Liver Transpl; 2008 Apr; 14(4):478-85. PubMed ID: 18324666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients.
    Sánchez-Pérez B; Aranda Narváez JM; Santoyo Santoyo J; Fernández-Aguilar JL; Suárez Muñoz MA; González-Sánchez AJ; Pérez Daga JA; Ramírez Plaza CP; Carrasco Campos J; Jiménez Mazure C; Becerra Ortíz R
    Transplant Proc; 2008 Nov; 40(9):2994-6. PubMed ID: 19010171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infection.
    Lee TC; Goss JA; Rooney CM; Heslop HE; Barshes NR; Caldwell YM; Gee AP; Scott JD; Savoldo B
    Clin Transplant; 2006; 20(6):689-94. PubMed ID: 17100717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of immune function test in monitoring immunosuppression in liver transplant recipients.
    Te HS; Dasgupta KA; Cao D; Satoskar R; Mohanty SR; Reau N; Millis JM; Jensen DM
    Clin Transplant; 2012; 26(6):826-32. PubMed ID: 22554357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orthotopic liver transplantation in human immunodeficiency virus (HIV)-positive patients: outcome of 7 patients from the Bonn cohort.
    Vogel M; Voigt E; Schäfer N; Goldmann G; Schwarz N; Kalff JC; Sauerbruch T; Wolff M; Rockstroh JK; Spengler U
    Liver Transpl; 2005 Dec; 11(12):1515-21. PubMed ID: 16315295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of lymphoproliferative disease after liver transplantation.
    Marqués E; Jiménez C; Manrique A; Vallejo GH; Clemares M; Ortega P; Moreno E
    Transplant Proc; 2008 Nov; 40(9):2988-9. PubMed ID: 19010169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of an immunological score to assess the risk of severe infection in heart recipients.
    Sarmiento E; Navarro J; Fernandez-Yañez J; Palomo J; Muñoz P; Carbone J
    Transpl Infect Dis; 2014 Oct; 16(5):802-12. PubMed ID: 25179534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretransplant lymphocyte count predicts the incidence of infection during the first two years after liver transplantation.
    Fernández-Ruiz M; López-Medrano F; Romo EM; Allende LM; Meneu JC; Fundora-Suárez Y; San-Juan R; Lizasoain M; Paz-Artal E; Aguado JM
    Liver Transpl; 2009 Oct; 15(10):1209-16. PubMed ID: 19790140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
    Murillas J; Rimola A; Laguno M; de Lazzari E; Rascón J; Agüero F; Blanco JL; Moitinho E; Moreno A; Miró JM;
    Liver Transpl; 2009 Sep; 15(9):1133-41. PubMed ID: 19718643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation.
    Porrini E; Delgado P; Alvarez A; Cobo M; Pérez L; González-Posada JM; Hortal L; Gallego R; García JJ; Checa M; Morales A; Salido E; Hernández D; Torres A
    Nephrol Dial Transplant; 2008 Apr; 23(4):1436-41. PubMed ID: 18029372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new side effect of immunosuppression: high incidence of hearing impairment after liver transplantation.
    Rifai K; Kirchner GI; Bahr MJ; Cantz T; Rosenau J; Nashan B; Klempnauer JL; Manns MP; Strassburg CP
    Liver Transpl; 2006 Mar; 12(3):411-5. PubMed ID: 16456830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors associated with cytomegalovirus infection in orthotopic liver transplant patients.
    Hoppe L; Marroni CA; Bressane R; Lago L; Schiavo FL; Cigerza GC; Brandão AB; Zanotelli ML; Cantisani GP
    Transplant Proc; 2006; 38(6):1922-3. PubMed ID: 16908324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.